Autres langues INVO Bioscience, Inc.

Actions

INVO

US44984F4019

Temps réel estimé Cboe BZX Autres places de cotation 20:32:11 06/05/2024			Varia. 5j.	Varia. 1 janv.
0,859 ^USD	-7,13 %		-16,79 %	-34,67 %

16/04	INVO Bioscience, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	NAYA Biosciences Inc. annonce la publication de nouvelles données concernant son anticorps bispécifique Flex-NK ciblant le CD38 dans le Blood Journal de la Société américaine d'hématologie	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Exploring Emerging Companies with Key Developments Garnering Attention: INBS, INVO, VTAK, RCAT, GCTK	22/04
Top Premarket Decliners	18/04
Sector Update: Health Care Stocks Retreating Late Afternoon	17/04
Top Midday Gainers	17/04
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	17/04
Top Premarket Gainers	17/04
INVO Reports Fourth Quarter and Full Year 2023 Financial Results	16/04
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K	16/04
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	08/04
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	05/04
INVO Bioscience : Private Placement - Form 8-K	01/04
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	09/02
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors	17/01
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	29/12
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K	28/12
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal	12/12
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	11/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues INVO Bioscience, Inc.

Actions

INVO

US44984F4019

Autres langues

Filtres